Company intelligence / Profile preview

NeuroVir Therapeutics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

NeuroVir Therapeutics was a private oncology-focused biotechnology company that developed modified herpes simplex virus vectors as oncolytic cancer therapeutics. The company operated in Vancouver, British Columbia and San Diego, California, and advanced two clinical-stage programs for glioblastoma and colorectal cancer metastatic to the liver. NeuroVir's core capability was an HSV-based oncolytic virus platform designed to selectively attack tumor tissue. In late 2000 and early 2001, the company was acquired by MediGene in a stock-for-stock transaction, and its programs and platform were folded into MediGene's oncology portfolio.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyGene therapy
Industry: Biotech

Beyond the preview

Go deeper on NeuroVir Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroVir Therapeutics.

Explore the full profile